Neuphoria Therapeutics Inc.
NEUP
$4.73
-$0.11-2.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 57.33% | 85.29% | 50.56% | 47.97% | 14.55% |
| Total Depreciation and Amortization | 0.24% | -0.12% | -0.03% | -0.03% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -290.99% | -819.35% | 38.85% | 39.99% | -72.29% |
| Change in Net Operating Assets | -54.59% | -332.24% | -68.27% | -68.27% | -- |
| Cash from Operations | 14.88% | -0.07% | 40.57% | 37.75% | -33.17% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -12.11% | -8.74% | -- |
| Cash from Investing | -- | -- | -12.11% | -8.74% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 7.60% | 4.15% | -- |
| Issuance of Common Stock | -- | -99.99% | -- | -- | -92.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -102.08% | 95.97% | 509.65% | 503.53% | 870.33% |
| Cash from Financing | -101.98% | -137.11% | 7,478.78% | 5,967.11% | 187.35% |
| Foreign Exchange rate Adjustments | -180.62% | 190.58% | 233.42% | 231.10% | 34,420.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -285.06% | -13.90% | 130.31% | 129.80% | 314.77% |
